

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 July 2020 (23.07.2020)



(10) International Publication Number
WO 2020/150473 A3

(51) International Patent Classification:

C07D 417/12 (2006.01) C07D 498/04 (2006.01)
C07D 417/14 (2006.01) C07D 495/04 (2006.01)
C07D 403/14 (2006.01) A61K 31/506 (2006.01)
C07D 491/107 (2006.01) A61P 3/06 (2006.01)
C07D 487/10 (2006.01) A61P 9/00 (2006.01)
C07D 471/04 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2020/013881

(22) International Filing Date:

16 January 2020 (16.01.2020)

(88) Date of publication of the international search report:

04 February 2021 (04.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/794,234 18 January 2019 (18.01.2019) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **SERRANO-WU, Michael H.**; 4 Elizabeth
Road, Belmont, MA 02478 (US). **CHAMBERS, Mark**;
Chesterford Research Park, Cambridge CB10 1XL (GB).
GOLDSMITH, Erica; Chesterford Research Park, Cam-
bridge CB10 1XL (GB). **TIERNEY, Jason**; Chester-
ford Research Park, Cambridge CB10 1XL (GB). **JAN-**
DU, Karamjit; Chesterford Research Park, Cambridge
CB10 1XL (GB). **CLARK, David**; Chesterford Research
Park, Cambridge CB10 1XL (GB). **HINCHLIFFE, Paul**;
Chesterford Research Park, Cambridge CB10 1XL (GB).

(74) Agent: **LU, Yong**; AstraZeneca, One MedImmune Way,
Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: PCSK9 INHIBITORS AND METHODS OF USE THEREOF

(57) Abstract: The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.

WO 2020/150473 A3